Skip to content
2000
Volume 24, Issue 5
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Histone deacetylases (HDACs) are a class of enzymes that are responsible for the removal of acetyl groups from the -N-acetyl lysine of histones, allowing histones to wrap DNA more tightly. HDACs play an essential role in many biological processes, such as gene regulation, transcription, cell proliferation, angiogenesis, migration, differentiation and metastasis, which make it an excellent target for anticancer drug discovery. The search for histone deacetylase inhibitors (HDACis) has been intensified, with numerous HDACis being discovered, and five of them have reached the market. However, currently available HDAC always suffers from several shortcomings, such as limited efficacy, drug resistance, and toxicity. Accordingly, dual-targeting HDACis have attracted much attention from academia to industry, and great advances have been achieved in this area. In this review, we summarize the progress on inhibitors with the capacity to concurrently inhibit tubulin polymerization and HDAC activity and their application in cancer treatment.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557523666230717110255
2024-03-01
2024-12-23
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557523666230717110255
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test